MktsMarkets

Dyne Therapeutics, Inc.
NASDAQ: DYNKey statistics
DYN News
Stories mentioning DYN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 100,889 | 95,431 | 97,219 | 99,236 | 106,447 | 81,804 | 92,800 | 62,263 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 125,276 | 116,129 | 113,892 | 115,791 | 122,372 | 97,108 | 105,659 | 71,962 |
| Operating Income (Loss) | (125,276) | (116,129) | (113,892) | (115,791) | (122,372) | (97,198) | (105,569) | (71,962) |
| Interest Income | ||||||||
| Interest Expense | 2,904 | 94.00 | 0.00 | |||||
| Other Expense | 4,422 | 4,174 | 5,851 | 4,934 | 7,011 | 7,566 | 8,534 | 6,860 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (120,854) | (111,955) | (108,041) | (110,857) | (115,361) | (89,542) | (97,125) | (65,102) |
| Earnings Per Share (Basic) | (0.73) | (0.69) | (0.76) | (0.97) | (1.05) | (0.90) | (0.96) | (0.70) |
| Earnings Per Share (Diluted) | (0.73) | (0.69) | (0.76) | (0.97) | (1.05) | (0.90) | (0.96) | (0.70) |
| Weighted Average Shares Outstanding (Basic) | ||||||||
| Weighted Average Shares Outstanding (Diluted) | ||||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About DYN
Dyne Therapeutics, Inc. (NASDAQ: DYN) is a stock listed on the Nasdaq Stock Market under the ticker symbol DYN. It last traded at $15.50 (Nov 20, 2026, 4:00 PM ET), down 3.3% on the day. That gives Dyne Therapeutics a market capitalisation of $2.9B.
Over the past 52 weeks DYN has traded between $14.00 and $27.30.
For the quarter ended Mar 31, 2026 it reported a net loss of $120.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$120.9M |
| Dec 31, 2025 | — | -$112.0M |
| Sep 30, 2025 | — | -$108.0M |
| Jun 30, 2025 | — | -$110.9M |
From Dyne Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…